经导管二尖瓣植入术治疗生物瓣衰败与成形环失败的结局
该单中心回顾性研究纳入2014年2月至2024年6月间88例经导管二尖瓣植入术(TMVI)患者,评估其临床结局及决定因素。结果显示院内、30天和1年死亡率分别为6.8%、5.8%和16.5%,不同入路和手术类型间无显著差异;术后平均压差≥5 mmHg者占58%,且与死亡风险增加相关。
要点
- TMVI术后1年死亡率16.5%,经房间隔与经心尖入路、瓣中瓣与环中瓣间无显著差异。
- 术后平均压差≥5 mmHg见于58%患者,多变量分析显示与死亡风险增加独立相关。
- 技术成功与死亡风险降低独立相关,1年随访仅1例二尖瓣反流≥2级。
核心结论
- TMVI治疗生物瓣衰败与成形环失败可获得可接受的中期死亡率,技术成功率高,二尖瓣反流近完全消除,但术后相关二尖瓣狭窄发生率高并可能影响死亡率。
研究设计与样本
- 回顾性单中心研究,纳入2014年2月至2024年6月间所有TMVI手术患者共88例。
主要发现
- 院内、30天和1年死亡率分别为6.8%、5.8%和16.5%。
- 1年随访仅1例患者二尖瓣反流≥2级。
- 术后平均压差≥5 mmHg见于51例(58%)。
临床怎么用
- TMVI可用于选定生物瓣衰败或成形环失败患者,但需关注术后平均压差升高及二尖瓣狭窄对中期生存的影响。
局限性
- 回顾性单中心设计,样本量88例,未进行临床 trial 注册。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Transcatheter mitral valve implantation (TMVI) is increasingly used in failed bioprostheses and annuloplasty rings as a less invasive alternative to redo-surgery in selected patients, with promising results. This retrospective single-centre study aims to provide additional insight into clinical outcomes and its determinants following TMVI. METHODS: Data of all TMVI procedures (n = 88) performed between February 2014 and June 2024 were retrospectively analysed. The primary end-points were 1-year mortality and the Mitral Valve Academic Research Consortium (MVARC) composite end-points. Secondary outcomes included complications and echocardiographic outcomes. RESULTS: Overall, in-hospital, 30-day, and 1-year mortality rates were 6.8%, 5.8%, and 16.5%, respectively. No significant differences were observed between transseptal and transapical approach (20.0 vs 13.2%, P = .439) or between valve-in-valve and valve-in-ring procedure (16.3 vs 18.2%, P = .828). At 1-year follow-up, only one patient presented with mitral regurgitation ≥ grade 2. However, a post-procedural mean pressure gradient (MPG) ≥5 mm Hg was observed in 51 patients (58%). In multivariate analysis, higher post-procedural MPG was associated with increased mortality risk (P = .047; hazard ratio [HR] = 1.23; 95% CI, 1.00-1.51), whereas technical success was associated with reduced mortality risk (P = .014; HR = 0.12; 95% CI, 0.02-0.65). CONCLUSIONS: Transcatheter mitral valve implantation provided acceptable mid-term mortality irrespective of procedure type and access route, with excellent technical success. Furthermore, mid-term follow-up showed near-complete elimination of mitral regurgitation. However, a high rate of post-procedural relevant mitral stenosis was observed, which may have an impact on mortality. In the light of the anticipated increase in TMVI procedures, we advocate for larger prospective studies to investigate the long-term determinants of mortality. CLINICAL TRIAL REGISTRATION: As this study was retrospective and based on previously collected clinical data, clinical trial registration was not required.
引用
- Lee CB, Schweiger V, Schwarzkopf D, et al. Outcomes of Transcatheter Mitral Valve Implantation for Failed Bioprostheses and Annuloplasty Rings. Eur J Cardiothorac Surg. 2026. PMID: 41530556. doi:10.1093/ejcts/ezag031
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。